Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Liabilities (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Total Liabilities for 9 consecutive years, with $98.1 million as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities fell 31.68% year-over-year to $98.1 million; the TTM value through Mar 2026 reached $98.1 million, down 31.68%, while the annual FY2025 figure was $107.6 million, 34.3% down from the prior year.
  • Total Liabilities hit $98.1 million in Q1 2026 for Bicycle Therapeutics, down from $107.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $234.1 million in Q2 2023 and bottomed at $98.1 million in Q1 2026.
  • Average Total Liabilities over 5 years is $162.3 million, with a median of $163.3 million recorded in 2025.
  • Year-over-year, Total Liabilities skyrocketed 74.56% in 2023 and then tumbled 34.3% in 2025.
  • Bicycle Therapeutics' Total Liabilities stood at $139.8 million in 2022, then soared by 60.49% to $224.4 million in 2023, then fell by 27.01% to $163.8 million in 2024, then crashed by 34.3% to $107.6 million in 2025, then fell by 8.87% to $98.1 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $98.1 million, $107.6 million, and $145.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.